5 stories mentioning SGX:42TUpdated 2d ago
Every FINWIRES story that references SGX:42T, newest first.
The Trendlines (SGX:42T) board approved an investment in the company's portfolio company, ProArc, by Librae Holdings, according to an after-market filing with the Singapore Exchange on Wednesday.Librae is deemed a controlling shareholder of Trendlines.
Tredlines (SGX:42T) portfolio company, Phytolon, completed a $23.6 million series B financing to commercialize its natural food colors in the U.S., according to a Thursday filing with the Singapore Exchange.The financing round was led by an unnamed strategic investor, with funding structured in three stages.The portfolio company focuses on fermentation-based natural color solutions.
The Trendlines (SGX:42T) signed a strategic distribution agreement with a US-based medical technology company, according to a Monday filing with the Singapore Exchange.Shares of the company were down nearly 2% in Tuesday trading.Under the agreement, the company's brand, ElastiMed will gain access to the US market for its MyoSleeve wearable compression device.MyoSleeve's technology aims at the treatment of venous and lymphatic conditions.
Trendlines Group (SGX:42T) said its board approved a capital injection into portfolio companies Ceretrieve and Vensica Medical by controlling shareholder Librae Holdings.Shares of the agrifood and med-tech company were down over 1% in Tuesday's afternoon trade.Librae will invest around $850,000 in the units. Additionally, Trendlines will infuse a total of $550,000 to the portfolio firms, according to a Monday filing with the Singapore Exchange.The funding is aimed at supporting the ongoing operations of the portfolio companies and helping them achieve successful exits, the filing said.Ceretrieve develops neurointerventional devices, while Vensica Medical specializes in bladder-targeted therapies.
The Trendlines (SGX:42T) subsidiary, Vensica Medical, received approval from the U.S. Food and Drug Administration (FDA) to initiate Phase 2 clinical trials for its VixE drug delivery system, according to a Monday filing with the Singapore Exchange.Shares of the medical and other services company were up nearly 5% in Tuesday trading.The needle-free delivery system is being developed for the treatment of overactive bladder, with the phase 2 study expected to conduct trials across around 210 patients in the U.S. and Europe.
